- Adds clinical-stage portfolio of oral small molecule Factor D inhibitors to Alexion’s pipeline - - Provides opportunity to enhance treatment for PNH patients experiencing extravascular hemolysis (EVH), potential first-in-class C3 glomerulopathy (C3G) therapy & promising development platform for
BLUE BELL, Pa. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Joseph Truitt , President and
– Danicopan Phase 2 PNH combination therapy topline data expected Q4 2019 – – Initiation of Phase 3 planned for early 2020 – BLUE BELL, Pa. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the
BLUE BELL, Pa. , Aug. 29, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Joseph Truitt , President and
– Danicopan (ACH-4471) Phase 2 combination therapy interim data showed clinically meaningful improvements in laboratory parameters of PNH; End-of-Phase 2 meeting activities initiated with FDA – – ACH-5228’s near complete and sustained inhibition of the alternative pathway and its tolerability
ACH-5228 delivers near complete and sustained inhibition of the complement alternative pathway Twice-daily oral administration to move forward in Phase 2 trials Investigational New Drug (IND) application to be submitted in fourth quarter of 2019 BLUE BELL, Pa.
BLUE BELL, Pa. , June 13, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Brian Di Donato , Chief Financial
BLUE BELL, Pa. , June 10, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the final data set for ACH-4471
- ACH-4471 increased hemoglobin and nearly eliminated the need for transfusions in patients with PNH being treated with C5 inhibitor, eculizumab - BLUE BELL, Pa. , May 17, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated
USPTO grants composition of matter patent for ACH-5548, Achillion’s 3rd clinical-stage asset BLUE BELL, Pa. , May 14, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) ), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families